- Home
- ANIX vs CNTB Comparison
ANIX vs CNTB Comparison
Compare ANIX & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANIX
- CNTB
- Stock Information
- Founded
- ANIX 1982
- CNTB 2012
- Country
- ANIX United States
- CNTB United States
- Employees
- ANIX N/A
- CNTB N/A
- Industry
- ANIX Biotechnology: Pharmaceutical Preparations
- CNTB Biotechnology: Pharmaceutical Preparations
- Sector
- ANIX Health Care
- CNTB Health Care
- Exchange
- ANIX Nasdaq
- CNTB Nasdaq
- Market Cap
- ANIX 101.4M
- CNTB 68.5M
- IPO Year
- ANIX 1987
- CNTB 2021
- Fundamental
- Price
- ANIX $3.08
- CNTB $1.21
- Analyst Decision
- ANIX Strong Buy
- CNTB Strong Buy
- Analyst Count
- ANIX 2
- CNTB 1
- Target Price
- ANIX $8.50
- CNTB $8.00
- AVG Volume (30 Days)
- ANIX 42.0K
- CNTB 27.9K
- Earning Date
- ANIX 10-29-2024
- CNTB 09-05-2024
- Dividend Yield
- ANIX N/A
- CNTB N/A
- EPS Growth
- ANIX N/A
- CNTB N/A
- EPS
- ANIX N/A
- CNTB N/A
- Revenue
- ANIX N/A
- CNTB $24,116,000.00
- Revenue This Year
- ANIX N/A
- CNTB N/A
- Revenue Next Year
- ANIX N/A
- CNTB $63.90
- P/E Ratio
- ANIX N/A
- CNTB N/A
- Revenue Growth
- ANIX N/A
- CNTB N/A
- 52 Week Low
- ANIX $2.15
- CNTB $0.68
- 52 Week High
- ANIX $5.13
- CNTB $2.84
- Technical
- Relative Strength Index (RSI)
- ANIX 41.08
- CNTB 45.22
- Support Level
- ANIX $2.95
- CNTB $1.22
- Resistance Level
- ANIX $3.11
- CNTB $1.44
- Average True Range (ATR)
- ANIX 0.12
- CNTB 0.12
- MACD
- ANIX -0.01
- CNTB -0.02
- Stochastic Oscillator
- ANIX 19.35
- CNTB 16.22
About ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc, a cancer-focused biotechnology company, developing vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.